Erudio Healtherudio.com
Drug
Alectinib trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying alectinib: CUPISCO. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 15 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| CUPISCO NCT03498521 · Hoffmann-La Roche | unfavourable cancer of unknown primary | Phase 2 | 358 | 62 | Deep | Oct 31, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ALEX NCT02075840 · Hoffmann-La Roche DeepView → | treatment-naive advanced ALK-positive non-small-cell lung cancer | Phase 3 | Deep | View | |||
| NAUTIKA1 NCT04302025 · Genentech, Inc. DeepView → | biomarker-selected resectable stages IB-III NSCLC | Phase 2 | Deep | View | |||
| MyPathway NCT02091141 · Genentech, Inc. DeepView → | advanced solid tumors with molecular alterations | Phase 2 | Deep | View | |||
| ROME NCT04591431 · Fondazione per la Medicina Personalizzata DeepView → | advanced solid tumors | Phase 2 | Deep | View | |||
| ALNEO NCT05015010 · Gruppo Oncologico Italiano di Ricerca Clinica DeepView → | ALK-positive locally advanced stage III NSCLC | Phase 2 | Deep | View | |||
| BFAST NCT03178552 · Hoffmann-La Roche DeepView → | advanced or metastatic non-small cell lung cancer | Phase 2/Phase 3 | Deep | View | |||
| ALKAZAR NCT06765109 · Nuvalent Inc. DeepView → | first-line ALK-positive advanced non-small cell lung cancer | Phase 3 | Deep | View | |||
| ALESIA NCT02838420 · Hoffmann-La Roche StandardView → | treatment-naive ALK-positive advanced non-small cell lung cancer | Phase 3 | Standard | View | |||
| ORCHARD NCT03944772 · AstraZeneca StandardView → | EGFR-mutated advanced NSCLC after first-line osimertinib | Phase 2 | Standard | View | |||
| HORIZON 1 NCT05170204 · Hoffmann-La Roche StandardView → | unresectable stage III non-small cell lung cancer | Phase 3 | Standard | View | |||
| ALTA-3 NCT03596866 · Takeda FocusedView → | crizotinib-resistant advanced ALK-positive non-small-cell lung cancer | Phase 3 | Focused | View | |||
| NCI-NRG ALK Protocol NCT03737994 · National Cancer Institute (NCI) FocusedView → | previously treated ALK-positive stage IV non-squamous NSCLC | Phase 2 | Focused | View | |||
| NP28673 NCT01801111 · Hoffmann-La Roche FocusedView → | crizotinib-resistant ALK-positive non-small cell lung cancer | Phase 1/Phase 2 | Focused | View | |||
| NP28761 NCT01871805 · Hoffmann-La Roche FocusedView → | ALK-positive crizotinib-resistant non-small cell lung cancer | Phase 1/Phase 2 | Focused | View | |||
| NCT02013219 NCT02013219 · Hoffmann-La Roche FocusedView → | advanced non-small cell lung cancer | Phase 1 | Focused | View | |||